Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 1.00 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709778 | 1.00 | CES1 (1.00) | CES1FAAHCES2AKR1B1CPA1 | |
| SCHEMBL583920 | 0.88 | CES1 (0.78) | CES1FAAHMEN1KMT2AHDAC8 | |
| SCHEMBL4753311 | 0.84 | CES1 (0.71) | CES1FAAHCES2AKR1B1CPA1 | |
| SCHEMBL2381708 | 0.83 | CES1 (0.69) | CES1HDAC6 | |
| SCHEMBL16405134 | 0.83 | CES1 (0.70) | CES1FAAHCES2AKR1B1CPA1 | |
| SCHEMBL13498524 | 0.83 | CES1 (0.70) | CES1FAAHCES2AKR1B1CPA1 | |
| SCHEMBL9314779 | 0.83 | CES1 (0.70) | CES1FAAHCES2AKR1B1CPA1 | |
| SCHEMBL10433444 | 0.83 | CES1 (0.70) | CES1FAAHCES2AKR1B1CPA1 | |
| Phenylacetic Acid SCHEMBL27489228 | 0.80 | AKR1B1 (0.74) | CES1CES2AKR1B1CPA1PAM | |
| SCHEMBL10431529 | 0.80 | CES1 (0.67) | CES1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109134376-B | Synthetic method of 3-trifluoroacetyl indazole derivative | 华南理工大学 | 2021-09-21 | — | — | CN | claimed |
| CN-107445880-B | A kind of trifluoromethyl modification AβThe synthetic method of -42 inhibitor structure analogs | 华南理工大学 | 2019-07-16 | — | — | CN | claimed |
| CN-107445880-A | A kind of trifluoromethyl modifies AβThe synthetic method of 42 inhibitor structure analogs | 华南理工大学 | 2017-12-08 | — | — | CN | claimed |
| WO-2009032840-A1 | FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | claimed |
| EP-0646113-B1 | SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AG (DE) | 1996-12-18 | — | — | EP | claimed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025230736-A1 | ENGINEERED BIOCATALYSTS FOR THE SYNTHESIS OF GAMMA-HYDROXY AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20240026396-A1 | METHOD FOR PRODUCING TERTIARY BETA-HYDROXY-ALPHA-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026396-A1 | METHOD FOR PRODUCING TERTIARY BETA-HYDROXY-ALPHA-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026396-A1 | METHOD FOR PRODUCING TERTIARY BETA-HYDROXY-ALPHA-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| EP-0485716-B1 | Process for the preparation of insecticidal, acaricidal and nematicidal 4-substituted-5-(trifluoromethyl)pyrrole-3-carbonitrile compounds | AMERICAN CYANAMID CO (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0623103-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES. | HOECHST SCHERING AGREVO GMBH (DE) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014054-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1993-07-22 | — | — | WO | disclosed |
| EP-0485716-A1 | Process for the preparation of insecticidal, acaricidal and nematicidal 4-substituted-5-(trifluoromethyl)pyrrole-3-carbonitrile compounds | AMERICAN CYANAMID COMPANY (US) | 1992-05-20 | — | — | EP | disclosed |
| US-5106985-A | PROCESS FOR THE PREPARATION OF INSECTICIDAL, NEMATICIDAL AND ACARICIDAL 4-SUBSTITUTED-5-(TRIFLUOROMETHYL)PYRROLE-3-CARBONITRILE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0253503-B1 | SUBSTITUTED ANILIDES HAVING ANTIANDROGENIC PROPERTIES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-12-11 | — | — | EP | disclosed |
| US-4130554-A | ANTISECRETORY, GROWTH INHIBITORS, LOWER BLOOD GLUCOSE | MERCK & CO., INC. (US) | 1978-12-19 | — | — | US | disclosed |
| US-3963691-A | POLYPEPTIDES, PEPTIZATION | MERCK & CO., INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | CES1 2029/4885FAAH 2756/4885CES2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.